Midway through trading Monday, the Dow traded up 1.64% to 26503.64 while the NASDAQ rose 1.92% to 10,821.08. The S&P also rose, gaining 1.42% to 3,230.31.
The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 3,304,940 cases with around 135,200 deaths. Brazil confirmed a total of over 1,864,680 COVID-19 cases with 72,100 deaths, while India reported a total of at least 878,250 confirmed cases and 23,170 deaths. In total, there were at least 12,910,350 cases of COVID-19 worldwide with over 569,120 deaths, according to data compiled by Johns Hopkins University.
Leading and Lagging Sectors
Consumer discretionary shares rose 2.5% on Monday. Meanwhile, top gainers in the sector included Vuzix Corporation VUZI 13.94%, up 15%, and Tesla, Inc. TSLA 13.05%, up 14%.
In trading on Monday, energy shares fell 0.2%.
Top Headline
Pepsico reported quarterly earnings of $1.32 per share, beating analysts’ estimates of $1.25 per share. The company reported sales of $15.95 billion, exceeding expectations of $15.38 billion.
Equities Trading UP
Equillium, Inc. EQ 155.8% shares shot up 156% to $8.17 after the company disclosed that Itolizumab significantly reduced mortality in coronavirus patients, according to a clinical trial conducted in India by its partner Biocon.
Shares of electroCore, Inc. ECOR 183.53% got a boost, shooting 175% to $2.3399 after the company announced it has received FDA emergency use authorization for the use of gammaCore Sapphire CV for acute treatment of asthma exacerbations in COVID-19 patients.
Benefytt Technologies, Inc. BFYT 37.68% shares were also up, gaining 38% to $30.77 after the company agreed to be acquired by Madison Dearborn Partners for $31 per share.
Equities Trading DOWN
Celsion Corporation CLSN 61.59% shares tumbled 63% to $1.31 after the company received a recommendation from its independent data monitoring committee to consider stopping its Phase 3 OPTIMA study due to efficacy concerns.
Shares of NextCure, Inc. NXTC 44.98% were down 46% to $9.69 after the company said it would not advance its non-small cell lung cancer and ovarian cancer studies. The company's chief medical officer also departed the company. SunTrust Robinson Humphrey downgraded NextCure from Buy to Hold and lowered the price target from $78 to $13.
Gritstone Oncology, Inc. GRTS 50.99% was down, falling 47% to $4.25 after the company gave an update on its immunotherapy product candidates.
Commodities
In commodity news, oil traded down 0.1% to $40.53, while gold traded up 0.4% to $1,809.40.
Silver traded up 3.1% Monday to $19.635, while copper rose 2.3% to $2.9645.
Euro zone
European shares were higher today. The eurozone’s STOXX 600 rose 0.83%, the Spanish Ibex Index rose 1.32%, while Italy’s FTSE MIB Index gained 0.95%. Meanwhile, the German DAX 30 gained 1.08%, French CAC 40 gained 1.41% and UK shares rose 1.3%.
Economics
Federal Reserve Bank of Dallas President Robert Kaplan will speak at 1:00 p.m. ET.
The U.S. Treasury budget report for June is scheduled for release at 2:00 p.m. ET.
Benzinga does not provide investment advice. All rights reserved.
Recommended Content
Editors’ Picks
EUR/USD trades weak below 1.0800 amid Good Friday lull, ahead of US PCE
EUR/USD remains depressed below 1.0800 after soft French inflation data, amid minimal volatility and thin liquidity on Good Friday. The pair keenly awaits the US PCE inflation data and Fed Chair Powell's speech for fresh hints on next week's price action.
GBP/USD holds steady above 1.2600 as markets stay calm on Good Friday
GBP/USD trades sideways above 1.2600 amid a typical Good Friday trading lull. A broadly firmer US Dollar could keep any upside attempts limited in the pair ahead of the US PCE inflation data and Fed Chair Powell's appearance.
Gold price sits at all-time highs above $2,230, US PCE eyed
Gold price hit all-time highs at $2,236 on Thursday to finish Q1 2024 with a bang. Most major world markets, including the US are closed due to Holy Friday, leaving volatility around Gold price highly subdued. US PCE inflation and Powell are awaited.
Jito price could hit $6 as JTO coils up inside this bullish pattern
Jito (JTO) price has been on an uptrend since forming a local bottom in early January. Since then, JTO has revisited the key swing point formed in early December, suggesting the bulls’ intention to move higher.
Key events in developed markets next week
Next week, the main focus will be inflation and the labour market in the Eurozone. We expect services inflation to be impacted by the easter effect, while the unemployment rate to be unchanged.